Key Highlights
- Common mRNA vaccines may double cancer survival when used in conjunction with immunotherapy.
- The study analyzed over 1,000 patients with lung cancer and melanoma treated at the University of Texas MD Anderson Cancer Center from 2019 to 2023.
- A significant increase in three-year overall survival was observed among “cold” tumors when both treatments were combined.
- Researchers are planning a large clinical trial to further investigate these findings.
New Hope for Cancer Patients: mRNA Vaccines and Immunotherapy
A groundbreaking study suggests that common mRNA vaccines, such as those used against COVID-19, may significantly enhance the effectiveness of immunotherapy in treating certain types of cancer. Researchers from the University of Florida and the University of Texas MD Anderson Cancer Center presented their findings at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin on October 19.
The study, which analyzed data from over 1,000 patients with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma, found that those who received both the mRNA vaccine and immunotherapy had a nearly doubled survival rate compared to those who only received immunotherapy. The average survival time for patients receiving both treatments was 37.3 months, while those on immunotherapy alone survived an average of 20.6 months.
Boosting Tumor Response
The research highlighted a particularly significant improvement in survival rates among “cold” tumors—those that are typically resistant to immunotherapy. According to the study, these patients saw their three-year overall survival rate increase nearly fivefold when both treatments were combined.
“The implications of this discovery are extraordinary,” said Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and senior researcher on the study. “This could revolutionize the entire field of oncologic care.” The results suggest that an “universal, off-the-shelf” vaccine might be developed to boost cancer patients’ immune response, significantly improving survival rates.
Replicating Findings in Animal Models
To further validate their findings, researchers replicated the outcome in mouse models. When mice received a combination of immunotherapy drugs and an mRNA vaccine targeting the COVID-19 spike protein, their tumors became more responsive to treatment. “This is exactly the type of treatment benefit that we strive for,” Dr. Sayour added.
Non-mRNA vaccines for diseases like flu and pneumonia did not produce similar effects, indicating that the observed benefits are specific to mRNA technology. This specificity is critical in understanding how these vaccines might be used most effectively in clinical settings.
Looking Ahead: Clinical Trials
The researchers are now planning a large clinical trial through the UF-led OneFlorida+ Clinical Research Network, a consortium of hospitals, health centers, and clinics across several states. The goal is to confirm these findings in a prospective and randomized setting.
“Although not yet proven to be causal, this is the type of treatment benefit that we strive for,” said Duane Mitchell, M.D., Ph.D., director of the UF Clinical and Translational Science Institute. “The urgency and importance of doing the confirmatory work can’t be overstated.” The study was supported by various organizations, including the National Institutes of Health and the National Cancer Institute.
With these promising results, healthcare professionals are optimistic about the potential for mRNA vaccines to play a significant role in cancer treatment. If confirmed, this research could lead to new strategies that significantly improve patient outcomes and survival rates across multiple types of cancers.
